Aceto Completes 6th Acquisition, Expanding Its GMP Biopharmaceutical and Vaccine Manufacturing with Acquisition of A&C Bio Buffer 13th October 2021
Aceto, leading global provider of speciality materials for life sciences and advanced technology end markets, announced it’s acquisition of A&C Bio Buffer Ltd, a GMP (Good Manufacturing Practices) manufacturer of custom buffer and chemical blend products used in the manufacturing of biopharmaceutical drug products. This transaction complements Aceto’s acquisition earlier this year of A&C, a global manufacturer of GMP speciality excipients and custom process solutions, and reinforces the company’s expanded business development efforts in the biopharmaceutical sector.
” A&C Bio Buffer is a natural add-on to our acquisition of A&C and aligns with our commitments to the biopharmaceutical space,” said Giles Cottier Chief Executive Officer of Aceto. It is a nimble, highly customer-centric organization serving some of the top biopharmaceutical manufacturers in Europe. Its rapid growth reflects a reputation for service and quality, which recently led to its key role in the raw material supply chain for COVID-19 vaccines. A&C Bio Buffer enhances our growing European manufacturing footprint and commercial presence.. We believe the shared lineage reflected in an A&C Bio Buffer’s skills, culture and customer focus will further support our evolution as a leading supplier of critical raw materials in the life sciences sector.”
A&C Bio Buffer GMP manufacturers over 50 products including biological buffers, process solutions, cleaning solutions and WFI (Water for injection ) in its state-of-the-art facility in Limerick, Ireland. Aceto will continue to support A&C Bio Buffer’s manufacturing facilities and offices in Ireland. Financial terms we not disclosed.